Whether cannabis use causes psychosis, or vice versa, is a topic of debate. While determining causality can be extremely difficult, and researchers acknowledge more data is needed, there is evidence to support both theories: schizophrenia-related mechanisms lead to cannabis use and cannabis use leads to psychotic disorders.
In this talk, we will explore the history of cannabis potency and decriminalization, the advent of vaping and synthetic cannabis, current use trends, and epidemiological data and factors involved in the development of psychotic disorders among cannabis users. The talk will conclude with a discussion on implications for treatment, as well as larger, societal considerations, including disparities in societal responses to psychotic episodes and cannabis use in various racial and ethnic groups.
After attending this webinar, participants will be able to:
- Explain the history of increased potency and decriminalization of cannabis
- Reference research on the relationship between cannabis use and psychosis
- Consider treatment options for cannabis users who experience psychosis
Dr. Roeske is the Senior Director of the Center for Research and Innovation at Newport Healthcare, where he leads outcomes monitoring, measurement-based care, and behavioral health research. A licensed clinical psychologist with over 20 years of experience in clinical practice, executive leadership, and research, he has held executive roles in top treatment programs and served as a clinical director, therapist, and adjunct professor across diverse settings. He is a Board Member and Ethics Coordinator for the Pennsylvania Association of Addiction Professionals and serves on the NAATP FoRSE Advisory Board.